DHEA-S Lab Results: Normal Reference Ranges vs. Functional Optimal Levels

What DHEA-S Actually Measures

DHEA-S is the sulfated storage form of dehydroepiandrosterone, the most abundant adrenal androgen in human circulation. Your adrenal glands produce roughly 6 to 8 mg of DHEA daily during peak years, and the liver sulfates most of it into DHEA-S for extended half-life and tissue-level conversion [1].

Unlike cortisol, which swings dramatically across a 24-hour cycle, DHEA-S remains relatively flat throughout the day. That stability makes it a reliable single-draw biomarker. A morning blood sample captures the same clinical picture as an afternoon draw, which is why most endocrinologists prefer DHEA-S over unconjugated DHEA for routine screening [2].

The hormone sits upstream of both testosterone and estrogen. Peripheral tissues convert DHEA-S back into DHEA, then into androstenedione, and finally into sex steroids through local enzymatic activity. This "intracrine" pathway means DHEA-S acts as a reservoir. When circulating sex hormones drop (as in menopause or andropause), the clinical importance of that reservoir grows substantially [3].

DHEA-S production peaks between ages 20 and 25. By age 70, serum concentrations fall to 10-20% of their youthful peak, a decline steeper than any other adrenal hormone [1]. That trajectory has made DHEA-S one of the most studied biomarkers in aging research, even though clinical guidelines have not yet defined a universal "deficiency" threshold.

Standard Reference Ranges and Their Limitations

Most commercial laboratories report DHEA-S ranges derived from population-based sampling. A typical adult female range runs from about 35 to 430 µg/dL (ages 18-39) and drops to 12 to 154 µg/dL by ages 60-69 [4]. Male ranges are wider: roughly 85 to 690 µg/dL at ages 18-24, tapering to 28 to 175 µg/dL by the seventh decade.

These intervals describe statistical normality. They do not describe health. The reference population includes people with undiagnosed metabolic syndrome, chronic psychological stress, sedentary lifestyles, and subclinical adrenal insufficiency. A value at the 5th percentile "passes" the lab flag system even if it correlates with higher morbidity.

The 2006 Endocrine Society scientific statement on DHEA replacement acknowledged this limitation directly: "Normal ranges for DHEA and DHEA-S are broad and decline with age, making it difficult to define a clear cut-off for deficiency" [5]. That statement remains the Society's most recent position, and no update has established age-specific treatment thresholds.

Lab-to-lab variability compounds the problem. Immunoassay platforms (Roche Elecsys, Siemens Immulite, Abbott Architect) can yield DHEA-S values that differ by 15-25% on the same sample [6]. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) offers better precision but is not yet the default in most clinical labs. When comparing serial results, patients should use the same laboratory and assay platform each time.

The Functional Optimal Framework

Functional and integrative practitioners apply a different interpretive lens. Rather than asking "Is this value statistically normal for the population?" they ask "Is this value associated with the lowest disease risk and best symptom profile?"

Several large observational studies anchor this approach. The Rancho Bernardo Study (N=1,029 women, 15-year follow-up) found that women in the lowest quartile of DHEA-S had significantly higher cardiovascular mortality compared to those in upper quartiles, independent of traditional risk factors [7]. A separate analysis from the same cohort showed that men with DHEA-S levels in the bottom 25% had a 1.5-fold higher risk of death from ischemic heart disease over 12 years [8].

The European Male Ageing Study (EMAS, N=3,369) reported that men with DHEA-S below 1.5 µmol/L (approximately 55 µg/dL) had worse physical performance scores, higher fat mass, and more depressive symptoms compared to men above 4.0 µmol/L (approximately 149 µg/dL) [9]. These associations persisted after adjusting for age, BMI, and comorbidities.

From this evidence base, many clinicians set functional targets at the 50th to 75th percentile of the 25-to-35 age group. For women, that typically means 200 to 350 µg/dL. For men, 250 to 400 µg/dL. These are not guideline-endorsed thresholds. They are clinician-derived benchmarks grounded in epidemiological risk curves.

Dr. Thierry Hertoghe, a Belgian endocrinologist specializing in hormone optimization, has written: "The goal is not to push DHEA-S to the top of the range but to restore it to the level of a healthy 25-year-old, where epidemiological data consistently show the most favorable outcomes" [10].

Age-Related Decline: What the Drop Actually Looks Like

The term "adrenopause" describes the gradual fall in adrenal androgen output. It is not a discrete event like menopause. Production erodes year after year, beginning as early as age 30.

Quantified, the decline follows a predictable curve. A cross-sectional analysis of 2,084 healthy adults (Baltimore Longitudinal Study of Aging) measured a 2-3% annual decrease in DHEA-S after age 25 [1]. By age 50, the average person retains roughly 50% of peak levels. By 80, the figure drops to 10-20%.

This decline is not benign background noise. Low DHEA-S concentrations in middle-aged adults track with higher fasting glucose, greater waist circumference, elevated inflammatory markers (C-reactive protein, interleukin-6), and lower bone mineral density at the lumbar spine [11]. A 2020 meta-analysis published in Clinical Endocrinology (pooling 23 studies, N=27,938) concluded that each 1 µmol/L increase in DHEA-S was associated with a 6% lower risk of all-cause mortality in men, though the association in women was weaker and less consistent [12].

The clinical question is whether the decline is simply a biomarker of aging or a modifiable contributor to age-related disease. Current evidence does not settle that question definitively. Correlation is not causation. But the consistency of the association across diverse cohorts has driven interest in both monitoring and, in select cases, replacing DHEA-S.

High DHEA-S: When Levels Run Above Range

Elevated DHEA-S warrants a different diagnostic workup depending on the patient's sex, age, and symptoms.

In premenopausal women, DHEA-S above 500 µg/dL raises suspicion for polycystic ovary syndrome (PCOS), non-classic congenital adrenal hyperplasia (NCAH), or adrenal tumors. Roughly 20-30% of women with PCOS have elevated DHEA-S as their primary androgen abnormality, even when testosterone levels remain in range [13]. The Androgen Excess and PCOS Society recommends measuring DHEA-S alongside total and free testosterone in any woman presenting with hirsutism, acne, or oligomenorrhea [14].

Values exceeding 700 µg/dL in women or 800 µg/dL in men, especially with rapid virilization or Cushing-like features, mandate adrenal imaging. DHEA-S-secreting adrenal carcinomas are rare but aggressive. A CT of the adrenal glands is the standard first step [15].

For NCAH specifically, the gold standard confirmatory test is a cosyntropin (ACTH) stimulation test measuring 17-hydroxyprogesterone response [16]. Genetic testing for CYP21A2 mutations can follow when clinical suspicion is high.

Lowering an elevated DHEA-S depends on the underlying cause. In PCOS, combined oral contraceptives suppress adrenal androgen production and reduce DHEA-S by 30-50% within 3 to 6 months [13]. Low-dose dexamethasone (0.25 to 0.5 mg at bedtime) can suppress adrenal DHEA-S output, but long-term glucocorticoid use carries its own metabolic risks. Lifestyle interventions (caloric deficit, resistance training, improved sleep) reduce DHEA-S modestly in hyperandrogenic women by lowering insulin resistance, which drives adrenal androgen excess.

Low DHEA-S: Causes, Symptoms, and Clinical Significance

A DHEA-S level that falls below the age-adjusted 25th percentile, or below 100 µg/dL in a premenopausal woman or a man under 50, should trigger clinical evaluation.

Common causes include chronic glucocorticoid use (even inhaled corticosteroids at high doses), primary adrenal insufficiency (Addison disease), hypopituitarism, chronic opioid therapy, and prolonged physiological stress (critical illness, severe caloric restriction). Some antiepileptic drugs, particularly valproate and carbamazepine, also suppress adrenal androgen synthesis [17].

Symptoms of low DHEA-S overlap heavily with those of low testosterone and cortisol dysregulation: fatigue, reduced libido, depressed mood, poor stress tolerance, and loss of axillary or pubic hair. These symptoms lack specificity, which is precisely why lab measurement matters.

The Endocrine Society's 2014 guideline on adrenal insufficiency states: "DHEA replacement may be considered in women with adrenal insufficiency who have low libido, depressed mood, or low energy despite optimal glucocorticoid and mineralocorticoid replacement" [18]. The recommended starting dose is 25 to 50 mg of oral DHEA daily, taken in the morning, with follow-up DHEA-S measurement at 4 to 6 weeks to titrate.

A randomized controlled trial by Arlt et al. (N=24 women with Addison disease) demonstrated that 50 mg daily oral DHEA for 4 months significantly improved well-being scores (measured by the Short Form-36 Health Survey), reduced fatigue, and increased androgen levels to the normal premenopausal range compared to placebo [19]. A larger trial in the same population (N=106) confirmed improvements in mood and sexuality at 12 months [20].

For individuals without diagnosed adrenal insufficiency, the evidence for DHEA supplementation is less clear. The largest trial to date, DHEAge (N=280 healthy elderly adults), found no significant effect of 50 mg DHEA daily on body composition, physical performance, glucose metabolism, or bone mineral density after 1 year [21]. That study tempered enthusiasm for "anti-aging" DHEA use in otherwise healthy populations.

How to Raise DHEA-S Without Supplementation

Before reaching for a pill, several modifiable factors influence DHEA-S production.

Sleep is the most underestimated. Adrenal androgen synthesis follows a circadian pulse that depends on adequate slow-wave sleep. Chronic sleep restriction (fewer than 6 hours per night) has been associated with lower morning DHEA-S in cross-sectional analyses [22]. Restoring 7 to 8 hours of consolidated sleep is a first-line lifestyle intervention.

Exercise also contributes. A 2019 systematic review in Sports Medicine (12 studies, N=510) found that both resistance training and high-intensity interval training acutely raised DHEA-S concentrations, though chronic elevations were modest and primarily observed in previously sedentary older adults [23].

Stress management directly matters because cortisol and DHEA-S share the same precursor (pregnenolone). Chronic stress shunts pregnenolone toward cortisol synthesis and away from the DHEA pathway. While the "pregnenolone steal" model is simplified, human data show that sustained psychological stress correlates with a declining DHEA-S-to-cortisol ratio [24]. Interventions that lower cortisol (mindfulness-based stress reduction, cognitive behavioral therapy, adequate caloric intake) may indirectly support DHEA-S recovery.

Caloric sufficiency is non-negotiable. Severe caloric restriction suppresses the hypothalamic-pituitary-adrenal axis broadly, and DHEA-S drops alongside other adrenal outputs. Female athletes with relative energy deficiency in sport (RED-S) consistently show depressed DHEA-S relative to energy-matched controls [25].

Ordering and Interpreting the Test

DHEA-S is a standard serum test available at any commercial laboratory. No fasting is required. No specific time-of-day restriction applies, though morning draws between 7:00 and 10:00 AM align with most reference range derivation data.

Order DHEA-S (not unconjugated DHEA) for routine screening. DHEA has a half-life of only 15 to 30 minutes and fluctuates with pulsatile ACTH secretion, making it unreliable as a standalone marker. DHEA-S is the preferred analyte in all major guidelines addressing adrenal androgen assessment [5].

Interpret results in context. A 45-year-old woman with a DHEA-S of 120 µg/dL is "normal" by most lab standards. She is also at the 15th percentile for a 25-year-old and, according to observational data, in a risk bracket associated with lower bone density and worse quality-of-life scores [7][11]. Whether that warrants intervention depends on symptoms, clinical judgment, and patient preference.

Serial monitoring every 6 to 12 months is reasonable for patients on DHEA replacement, those recovering from adrenal stress, or individuals tracking the biomarker as part of a broader hormone panel. The Endocrine Society recommends checking DHEA-S (along with testosterone and androstenedione) 24 hours after the last DHEA dose when monitoring replacement therapy [18].

A single elevated or depressed result should always be confirmed with a repeat draw before initiating treatment. Assay interference from biotin supplementation (common in hair/nail vitamins) can falsely raise or depress immunoassay-based DHEA-S results. The FDA recommends stopping biotin at least 72 hours before any hormone blood draw [26].

When to Involve a Specialist

Primary care physicians can order and interpret DHEA-S in most clinical scenarios. Referral to endocrinology is appropriate when DHEA-S exceeds 700 µg/dL in women or 800 µg/dL in men, when adrenal imaging reveals a mass, when congenital adrenal hyperplasia is suspected, or when DHEA-S remains persistently low despite correction of identifiable causes.

Reproductive endocrinologists should evaluate women with elevated DHEA-S and concomitant infertility or menstrual irregularity. Pediatric endocrinologists manage premature adrenarche, a condition where DHEA-S rises before age 8 in girls or age 9 in boys and can signal early activation of the adrenal androgen pathway [27].

For patients considering DHEA supplementation outside of diagnosed adrenal insufficiency, a clinician experienced in hormone optimization should monitor not only DHEA-S but also downstream metabolites (testosterone, estradiol, androstenedione) to ensure the supplemented DHEA is converting through desired pathways and not accumulating as unwanted androgens or estrogens.

The minimum monitoring panel for anyone on DHEA replacement: DHEA-S, total testosterone, free testosterone, estradiol, and a comprehensive metabolic panel at baseline and at 6-week, 3-month, and 6-month intervals.